Biotech Values

[udrunkenmonkey]

<This is exactly what BMY was hoping for: the gp100 vaccine adds nothing to survival nor does it subtract from survival—it’s effectively a placebo. All of the observed benefit can thus be attributed to Ipilimumab.>

The survival benefits are certainly a step in the right direction, but 4 months may be a hard sell to patients given the possible adverse events.

Quality if life comes into play when one could develop rheumatoid arthritis or colitis to go along with the survival benefit.